| Published Application/Species/Sample/Dilution | Reference |
|---|
- immunohistochemistry - paraffin section; mouse; 1:100; fig s6n
| Xiong W, Gao X, Zhang T, Jiang B, Hu M, Bu X, et al. USP8 inhibition reshapes an inflamed tumor microenvironment that potentiates the immunotherapy. Nat Commun. 2022;13:1700 pubmed publisher |
- flow cytometry; mouse; 1:200; loading ...; fig 2f
| Moreira T, Mangani D, Cox L, Leibowitz J, Lobo E, Oliveira M, et al. PD-L1+ and XCR1+ dendritic cells are region-specific regulators of gut homeostasis. Nat Commun. 2021;12:4907 pubmed publisher |
- flow cytometry; mouse; 1:200; loading ...
| Van De Velde L, Allen E, Crawford J, Wilson T, Guy C, Russier M, et al. Neuroblastoma Formation Requires Unconventional CD4 T Cells and Arginase-1-Dependent Myeloid Cells. Cancer Res. 2021;81:5047-5059 pubmed publisher |
| Hutton C, Heider F, Blanco Gómez A, Banyard A, Kononov A, Zhang X, et al. Single-cell analysis defines a pancreatic fibroblast lineage that supports anti-tumor immunity. Cancer Cell. 2021;: pubmed publisher |
- flow cytometry; mouse; loading ...; fig 2a
| Ning Y, Ding J, Sun X, Xie Y, Su M, Ma C, et al. HDAC9 deficiency promotes tumor progression by decreasing the CD8+ dendritic cell infiltration of the tumor microenvironment. J Immunother Cancer. 2020;8: pubmed publisher |
- flow cytometry; mouse; 1:100
| Yamamoto K, Venida A, Yano J, Biancur D, Kakiuchi M, Gupta S, et al. Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I. Nature. 2020;581:100-105 pubmed publisher |
- flow cytometry; mouse; loading ...; fig s4
| Chen H, Cong X, Wu C, Wu X, Wang J, Mao K, et al. Intratumoral delivery of CCL25 enhances immunotherapy against triple-negative breast cancer by recruiting CCR9+ T cells. Sci Adv. 2020;6:eaax4690 pubmed publisher |
- flow cytometry; mouse; loading ...; fig 6s2
| Canel M, Taggart D, Sims A, Lonergan D, Waizenegger I, Serrels A. T-cell co-stimulation in combination with targeting FAK drives enhanced anti-tumor immunity. elife. 2020;9: pubmed publisher |
- flow cytometry; mouse; fig 1e
| Khorooshi R, Marczynska J, Dieu R, Wais V, Hansen C, Kavan S, et al. Innate signaling within the central nervous system recruits protective neutrophils. Acta Neuropathol Commun. 2020;8:2 pubmed publisher |
- mass cytometry; mouse; 3 ug/ml; loading ...; fig 5d
| Guo C, Allen B, Hiam K, Dodd D, Van Treuren W, Higginbottom S, et al. Depletion of microbiome-derived molecules in the host using Clostridium genetics. Science. 2019;366: pubmed publisher |
- flow cytometry; mouse; loading ...; fig s2d
| Di Pilato M, Kim E, Cadilha B, Prüßmann J, Nasrallah M, Seruggia D, et al. Targeting the CBM complex causes Treg cells to prime tumours for immune checkpoint therapy. Nature. 2019;570:112-116 pubmed publisher |
- flow cytometry; mouse; loading ...; fig 1b
| Mizuno R, Sugiura D, Shimizu K, Maruhashi T, Watada M, Okazaki I, et al. PD-1 Primarily Targets TCR Signal in the Inhibition of Functional T Cell Activation. Front Immunol. 2019;10:630 pubmed publisher |
- flow cytometry; mouse; 1:400; loading ...; fig 3f
| Hammerich L, Marron T, Upadhyay R, Svensson Arvelund J, Dhainaut M, Hussein S, et al. Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination. Nat Med. 2019;25:814-824 pubmed publisher |
- flow cytometry; mouse; loading ...; fig 4a
| Sato Y, Bolzenius J, Eteleeb A, Su X, Maher C, Sehn J, et al. CD4+ T cells induce rejection of urothelial tumors after immune checkpoint blockade. JCI Insight. 2018;3: pubmed publisher |
- flow cytometry; mouse; 1:200; loading ...; fig 4h
| Sang A, Danhorn T, Peterson J, Rankin A, O Connor B, Leach S, et al. Innate and adaptive signals enhance differentiation and expansion of dual-antibody autoreactive B cells in lupus. Nat Commun. 2018;9:3973 pubmed publisher |
- immunohistochemistry - frozen section; mouse; loading ...; fig 6
| Tilstra J, Avery L, Menk A, Gordon R, Smita S, Kane L, et al. Kidney-infiltrating T cells in murine lupus nephritis are metabolically and functionally exhausted. J Clin Invest. 2018;128:4884-4897 pubmed publisher |
- flow cytometry; mouse; loading ...; fig s6a
| Vendetti F, Karukonda P, Clump D, Teo T, Lalonde R, Nugent K, et al. ATR kinase inhibitor AZD6738 potentiates CD8+ T cell-dependent antitumor activity following radiation. J Clin Invest. 2018;128:3926-3940 pubmed publisher |
- flow cytometry; human; 1:200; loading ...; fig s4f
| Hailemichael Y, Woods A, Fu T, He Q, Nielsen M, Hasan F, et al. Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy. J Clin Invest. 2018;128:1338-1354 pubmed publisher |
- flow cytometry; mouse; loading ...; fig 3d
| Perry C, Muñoz Rojas A, Meeth K, Kellman L, Amezquita R, Thakral D, et al. Myeloid-targeted immunotherapies act in synergy to induce inflammation and antitumor immunity. J Exp Med. 2018;215:877-893 pubmed publisher |
- flow cytometry; mouse; loading ...; fig 1d
| Lynch A, Hawk W, Nylen E, Ober S, Autin P, Barber A. Adoptive transfer of murine T cells expressing a chimeric-PD1-Dap10 receptor as an immunotherapy for lymphoma. Immunology. 2017;152:472-483 pubmed publisher |
- flow cytometry; mouse; loading ...; fig 2b
| Kogo H, Shimizu M, Negishi Y, Uchida E, Takahashi H. Suppression of murine tumour growth through CD8+ cytotoxic T lymphocytes via activated DEC-205+ dendritic cells by sequential administration of ?-galactosylceramide in vivo. Immunology. 2017;151:324-339 pubmed publisher |
- flow cytometry; mouse; loading ...; fig 1c
| Huang A, Peng D, Guo H, Ben Y, Zuo X, Wu F, et al. A human programmed death-ligand 1-expressing mouse tumor model for evaluating the therapeutic efficacy of anti-human PD-L1 antibodies. Sci Rep. 2017;7:42687 pubmed publisher |
- flow cytometry; mouse; loading ...; fig 6c
| Yanagita T, Murata Y, Tanaka D, Motegi S, Arai E, Daniwijaya E, et al. Anti-SIRPα antibodies as a potential new tool for cancer immunotherapy. JCI Insight. 2017;2:e89140 pubmed publisher |
- flow cytometry; mouse; 1:100; loading ...; fig S5
| Troegeler A, Mercier I, Cougoule C, Pietretti D, Colom A, Duval C, et al. C-type lectin receptor DCIR modulates immunity to tuberculosis by sustaining type I interferon signaling in dendritic cells. Proc Natl Acad Sci U S A. 2017;114:E540-E549 pubmed publisher |
- flow cytometry; human; loading ...; fig 4c
- flow cytometry; mouse; loading ...; fig 4c
| Jirmo A, Daluege K, Happle C, Albrecht M, Dittrich A, Busse M, et al. IL-27 Is Essential for Suppression of Experimental Allergic Asthma by the TLR7/8 Agonist R848 (Resiquimod). J Immunol. 2016;197:4219-4227 pubmed |
- flow cytometry; mouse; 1:800; loading ...; fig 3a
| Starobinets H, Ye J, Broz M, Barry K, Goldsmith J, Marsh T, et al. Antitumor adaptive immunity remains intact following inhibition of autophagy and antimalarial treatment. J Clin Invest. 2016;126:4417-4429 pubmed publisher |
- flow cytometry; mouse; fig 4
| Pizzolla A, Oh D, Luong S, Prickett S, Henstridge D, Febbraio M, et al. High Fat Diet Inhibits Dendritic Cell and T Cell Response to Allergens but Does Not Impair Inhalational Respiratory Tolerance. PLoS ONE. 2016;11:e0160407 pubmed publisher |
- blocking or activating experiments; mouse; fig 6
- flow cytometry; mouse; fig 5
| Seifert A, Zeng S, Zhang J, Kim T, Cohen N, Beckman M, et al. PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors. Clin Cancer Res. 2017;23:454-465 pubmed publisher |
- flow cytometry; mouse; loading ...; fig 3e
| Haribhai D, Ziegelbauer J, Jia S, Upchurch K, Yan K, Schmitt E, et al. Alternatively Activated Macrophages Boost Induced Regulatory T and Th17 Cell Responses during Immunotherapy for Colitis. J Immunol. 2016;196:3305-17 pubmed publisher |
- flow cytometry; mouse; fig 1
| Foy S, Sennino B, dela Cruz T, Cote J, Gordon E, Kemp F, et al. Poxvirus-Based Active Immunotherapy with PD-1 and LAG-3 Dual Immune Checkpoint Inhibition Overcomes Compensatory Immune Regulation, Yielding Complete Tumor Regression in Mice. PLoS ONE. 2016;11:e0150084 pubmed publisher |
- immunohistochemistry - paraffin section; mouse; 1:150; fig 4b
- flow cytometry; mouse
| Azpilikueta A, Agorreta J, Labiano S, Pérez Gracia J, Sánchez Paulete A, Aznar M, et al. Successful Immunotherapy against a Transplantable Mouse Squamous Lung Carcinoma with Anti-PD-1 and Anti-CD137 Monoclonal Antibodies. J Thorac Oncol. 2016;11:524-36 pubmed publisher |
- flow cytometry; mouse; 1:200; fig 5
| Aloulou M, Carr E, Gador M, Bignon A, Liblau R, Fazilleau N, et al. Follicular regulatory T cells can be specific for the immunizing antigen and derive from naive T cells. Nat Commun. 2016;7:10579 pubmed publisher |
- flow cytometry; mouse; loading ...; fig 5a
| Ngiow S, Young A, Jacquelot N, Yamazaki T, Enot D, Zitvogel L, et al. A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1. Cancer Res. 2015;75:3800-11 pubmed publisher |
- flow cytometry; mouse; fig 3
| Imai Y, Ayithan N, Wu X, Yuan Y, Wang L, Hwang S. Cutting Edge: PD-1 Regulates Imiquimod-Induced Psoriasiform Dermatitis through Inhibition of IL-17A Expression by Innate γδ-Low T Cells. J Immunol. 2015;195:421-5 pubmed publisher |
- blocking or activating experiments; mouse; fig 5
| Okamura T, Sumitomo S, Morita K, Iwasaki Y, Inoue M, Nakachi S, et al. TGF-β3-expressing CD4+CD25(-)LAG3+ regulatory T cells control humoral immune responses. Nat Commun. 2015;6:6329 pubmed publisher |
- blocking or activating experiments; mouse; fig 6
| McKay J, Egan R, Yammani R, Chen L, Shin T, Yagita H, et al. PD-1 suppresses protective immunity to Streptococcus pneumoniae through a B cell-intrinsic mechanism. J Immunol. 2015;194:2289-99 pubmed publisher |
| Peymanfar Y, Mahjour F, Shrestha N, de la Cueva A, Chen Y, Huang S, et al. The Lysyl Oxidase G473A Polymorphism Exacerbates Oral Cancer Development in Humans and Mice. Int J Mol Sci. 2023;24: pubmed publisher |
| Li Z, Wang F, Dang J, Cheng F, Zheng F. Bidirectional regulation between tumor cell-intrinsic PD-L1 and TGF-β1 in epithelial-to-mesenchymal transition in melanoma. Transl Cancer Res. 2022;11:3698-3710 pubmed publisher |
| Moore A, Vivanco Gonzalez N, Plummer K, Mitchel O, Kaur H, Rivera M, et al. Gestationally dependent immune organization at the maternal-fetal interface. Cell Rep. 2022;41:111651 pubmed publisher |
| Lin A, De Backer J, Quatannens D, Cuypers B, Verswyvel H, De La Hoz E, et al. The effect of local non-thermal plasma therapy on the cancer-immunity cycle in a melanoma mouse model. Bioeng Transl Med. 2022;7:e10314 pubmed publisher |
| Zhao T, Liu S, Ding X, Johnson E, Hanna N, Singh K, et al. Lysosomal acid lipase, CSF1R, and PD-L1 determine functions of CD11c+ myeloid-derived suppressor cells. JCI Insight. 2022;7: pubmed publisher |
| Sun Y, Zhang Z, Zhang C, Zhang N, Wang P, Chu Y, et al. An effective therapeutic regime for treatment of glioma using oncolytic vaccinia virus expressing IL-21 in combination with immune checkpoint inhibition. Mol Ther Oncolytics. 2022;26:105-119 pubmed publisher |
| Li H, Xiao Y, Li Q, Yao J, Yuan X, Zhang Y, et al. The allergy mediator histamine confers resistance to immunotherapy in cancer patients via activation of the macrophage histamine receptor H1. Cancer Cell. 2022;40:36-52.e9 pubmed publisher |
| Kiritsy M, McCann K, MOTT D, Holland S, Behar S, Sassetti C, et al. Mitochondrial respiration contributes to the interferon gamma response in antigen-presenting cells. elife. 2021;10: pubmed publisher |
| Iwai T, Sugimoto M, Patel H, Yorozu K, Kurasawa M, Kondoh O. Anti-VEGF Antibody Protects against Alveolar Exudate Leakage Caused by Vascular Hyperpermeability, Resulting in Mitigation of Pneumonitis Induced by Immunotherapy. Mol Cancer Ther. 2021;20:2519-2526 pubmed publisher |
| Kong F, Sun K, Zhu J, Li F, Lin F, Sun X, et al. PD-L1 Improves Motor Function and Alleviates Neuropathic Pain in Male Mice After Spinal Cord Injury by Inhibiting MAPK Pathway. Front Immunol. 2021;12:670646 pubmed publisher |
| Petty A, Dai R, Lapalombella R, Baiocchi R, Benson D, Li Z, et al. Hedgehog-induced PD-L1 on tumor-associated macrophages is critical for suppression of tumor-infiltrating CD8+ T cell function. JCI Insight. 2021;6: pubmed publisher |
| Zhang D, Reyes R, Osta E, Kari S, Gupta H, Padrón A, et al. Bladder cancer cell-intrinsic PD-L1 signals promote mTOR and autophagy activation that can be inhibited to improve cytotoxic chemotherapy. Cancer Med. 2021;10:2137-2152 pubmed publisher |
| Schofield D, Percival Alwyn J, Rytelewski M, Hood J, Rothstein R, Wetzel L, et al. Activity of murine surrogate antibodies for durvalumab and tremelimumab lacking effector function and the ability to deplete regulatory T cells in mouse models of cancer. MAbs. 2021;13:1857100 pubmed publisher |
| Sano Y, Yoshida T, Choo M, Jiménez Andrade Y, Hill K, Georgopoulos K, et al. Multiorgan Signaling Mobilizes Tumor-Associated Erythroid Cells Expressing Immune Checkpoint Molecules. Mol Cancer Res. 2021;19:507-515 pubmed publisher |
| Liu X, Bao X, Hu M, Chang H, Jiao M, Cheng J, et al. Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer. Nature. 2020;588:693-698 pubmed publisher |
| Lee H, Park J, Yoo H, Lee H, Lee B, Kim J. The Selenoprotein MsrB1 Instructs Dendritic Cells to Induce T-Helper 1 Immune Responses. Antioxidants (Basel). 2020;9: pubmed publisher |
| Tanaka Y, Wada H, Goto R, Osada T, Yamamura K, Fukaya S, et al. TAS0314, a novel multi-epitope long peptide vaccine, showed synergistic antitumor immunity with PD-1/PD-L1 blockade in HLA-A*2402 mice. Sci Rep. 2020;10:17284 pubmed publisher |
| Jeon I, Lee J, Shin K, Kang T, Park M, Seo H, et al. Enhanced Immunogenicity of Engineered HER2 Antigens Potentiates Antitumor Immune Responses. Vaccines (Basel). 2020;8: pubmed publisher |
| Iida Y, Yoshikawa R, Murata A, Kotani H, Kazuki Y, Oshimura M, et al. Local injection of CCL19-expressing mesenchymal stem cells augments the therapeutic efficacy of anti-PD-L1 antibody by promoting infiltration of immune cells. J Immunother Cancer. 2020;8: pubmed publisher |
| Muhammad F, Avalos P, Mursalin M, Ma J, Callegan M, Lee D. Kallistatin Attenuates Experimental Autoimmune Uveitis by Inhibiting Activation of T Cells. Front Immunol. 2020;11:975 pubmed publisher |
| Muhammad F, Wang D, McDonald T, Walsh M, Drenen K, Montieth A, et al. TIGIT+ A2Ar-Dependent anti-uveitic Treg cells are a novel subset of Tregs associated with resolution of autoimmune uveitis. J Autoimmun. 2020;111:102441 pubmed publisher |
| Tan Z, Chiu M, Yan C, Wong Y, Huang H, Man K, et al. Antimesothelioma Immunotherapy by CTLA-4 Blockade Depends on Active PD1-Based TWIST1 Vaccination. Mol Ther Oncolytics. 2020;16:302-317 pubmed publisher |
| Wang G, Kang X, Chen K, Jehng T, Jones L, Chen J, et al. An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses. Nat Commun. 2020;11:1395 pubmed publisher |
| Liu C, Schaettler M, Blaha D, Bowman Kirigin J, Kobayashi D, Livingstone A, et al. Treatment of an aggressive orthotopic murine glioblastoma model with combination checkpoint blockade and a multivalent neoantigen vaccine. Neuro Oncol. 2020;22:1276-1288 pubmed publisher |
| Sung Y, Jin P, Chu L, Hsu F, Wang M, Chang C, et al. Delivery of nitric oxide with a nanocarrier promotes tumour vessel normalization and potentiates anti-cancer therapies. Nat Nanotechnol. 2019;14:1160-1169 pubmed publisher |
| Jiao S, Subudhi S, Aparicio A, Ge Z, Guan B, Miura Y, et al. Differences in Tumor Microenvironment Dictate T Helper Lineage Polarization and Response to Immune Checkpoint Therapy. Cell. 2019;179:1177-1190.e13 pubmed publisher |
| Nambiar D, Aguilera T, Cao H, Kwok S, Kong C, Bloomstein J, et al. Galectin-1-driven T cell exclusion in the tumor endothelium promotes immunotherapy resistance. J Clin Invest. 2019;129:5553-5567 pubmed publisher |
| Mao W, Ghasemzadeh A, Freeman Z, Obradovic A, Chaimowitz M, Nirschl T, et al. Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition. J Immunother Cancer. 2019;7:277 pubmed publisher |
| Zhou L, Mudianto T, Ma X, Riley R, Uppaluri R. Targeting EZH2 Enhances Antigen Presentation, Antitumor Immunity, and Circumvents Anti-PD-1 Resistance in Head and Neck Cancer. Clin Cancer Res. 2019;: pubmed publisher |
| Mitchell L, Yagiz K, Hofacre A, Viaud S, Munday A, Espinoza F, et al. PD-L1 checkpoint blockade delivered by retroviral replicating vector confers anti-tumor efficacy in murine tumor models. Oncotarget. 2019;10:2252-2269 pubmed publisher |
| Norton T, Zhen A, Tada T, Kim J, Kitchen S, Landau N. Lentiviral Vector-Based Dendritic Cell Vaccine Suppresses HIV Replication in Humanized Mice. Mol Ther. 2019;27:960-973 pubmed publisher |
| Gong B, Kiyotani K, Sakata S, Nagano S, Kumehara S, Baba S, et al. Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer. J Exp Med. 2019;: pubmed publisher |
| Straub T, Pircher H. Enhancing immunity prevents virus-induced T-cell-mediated immunopathology in B cell-deficient mice. Eur J Immunol. 2019;49:782-789 pubmed publisher |
| Yahata T, Mizoguchi M, Kimura A, Orimo T, Toujima S, Kuninaka Y, et al. Programmed cell death ligand 1 disruption by clustered regularly interspaced short palindromic repeats/Cas9-genome editing promotes antitumor immunity and suppresses ovarian cancer progression. Cancer Sci. 2019;110:1279-1292 pubmed publisher |
| Cheng W, Tsui Y, Ragusa S, Koelzer V, Mina M, Franco F, et al. Uncoupling protein 2 reprograms the tumor microenvironment to support the anti-tumor immune cycle. Nat Immunol. 2019;20:206-217 pubmed publisher |
| Ding L, Kim H, Wang Q, Kearns M, Jiang T, Ohlson C, et al. PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer. Cell Rep. 2018;25:2972-2980.e5 pubmed publisher |
| Wu F, Xu P, Chow A, Man S, Kruger J, Khan K, et al. Pre- and post-operative anti-PD-L1 plus anti-angiogenic therapies in mouse breast or renal cancer models of micro- or macro-metastatic disease. Br J Cancer. 2019;120:196-206 pubmed publisher |
| Mastroianni J, Stickel N, Andrlova H, Hanke K, Melchinger W, Duquesne S, et al. miR-146a Controls Immune Response in the Melanoma Microenvironment. Cancer Res. 2019;79:183-195 pubmed publisher |
| Wu B, Sun X, Gupta H, Yuan B, Li J, Ge F, et al. Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer. Oncoimmunology. 2018;7:e1500107 pubmed publisher |
| Knier B, Hiltensperger M, Sie C, Aly L, Lepennetier G, Engleitner T, et al. Myeloid-derived suppressor cells control B cell accumulation in the central nervous system during autoimmunity. Nat Immunol. 2018;19:1341-1351 pubmed publisher |
| Gunda V, Gigliotti B, Ndishabandi D, Ashry T, McCarthy M, Zhou Z, et al. Combinations of BRAF inhibitor and anti-PD-1/PD-L1 antibody improve survival and tumour immunity in an immunocompetent model of orthotopic murine anaplastic thyroid cancer. Br J Cancer. 2018;119:1223-1232 pubmed publisher |
| Giles D, Duncker P, Wilkinson N, Washnock Schmid J, Segal B. CNS-resident classical DCs play a critical role in CNS autoimmune disease. J Clin Invest. 2018;128:5322-5334 pubmed publisher |
| Bisetto S, Whitaker Menezes D, Wilski N, Tuluc M, Curry J, Zhan T, et al. Monocarboxylate Transporter 4 (MCT4) Knockout Mice Have Attenuated 4NQO Induced Carcinogenesis; A Role for MCT4 in Driving Oral Squamous Cell Cancer. Front Oncol. 2018;8:324 pubmed publisher |
| He Y, Yuan X, Li Y, Zhong C, Liu Y, Qian H, et al. Loss of Gαq impairs regulatory B-cell function. Arthritis Res Ther. 2018;20:186 pubmed publisher |
| Shi J, Hou S, Fang Q, Liu X, Liu X, Qi H. PD-1 Controls Follicular T Helper Cell Positioning and Function. Immunity. 2018;49:264-274.e4 pubmed publisher |
| Stathopoulou C, Gangaplara A, Mallett G, Flomerfelt F, Liniany L, Knight D, et al. PD-1 Inhibitory Receptor Downregulates Asparaginyl Endopeptidase and Maintains Foxp3 Transcription Factor Stability in Induced Regulatory T Cells. Immunity. 2018;49:247-263.e7 pubmed publisher |
| Li J, Byrne K, Yan F, Yamazoe T, Chen Z, Baslan T, et al. Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy. Immunity. 2018;49:178-193.e7 pubmed publisher |
| Xiao W, Klement J, Lu C, Ibrahim M, Liu K. IFNAR1 Controls Autocrine Type I IFN Regulation of PD-L1 Expression in Myeloid-Derived Suppressor Cells. J Immunol. 2018;201:264-277 pubmed publisher |
| Chaganty B, Qiu S, Gest A, Lu Y, Ivan C, Calin G, et al. Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFN? secretion. Cancer Lett. 2018;430:47-56 pubmed publisher |
| Crosby E, Wei J, Yang X, Lei G, Wang T, Liu C, et al. Complimentary mechanisms of dual checkpoint blockade expand unique T-cell repertoires and activate adaptive anti-tumor immunity in triple-negative breast tumors. Oncoimmunology. 2018;7:e1421891 pubmed publisher |
| Panduro M, Benoist C, Mathis D. Treg cells limit IFN-? production to control macrophage accrual and phenotype during skeletal muscle regeneration. Proc Natl Acad Sci U S A. 2018;115:E2585-E2593 pubmed publisher |
| Hoves S, Ooi C, Wolter C, Sade H, Bissinger S, Schmittnaegel M, et al. Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity. J Exp Med. 2018;215:859-876 pubmed publisher |
| Kitamura T, Doughty Shenton D, Cassetta L, Fragkogianni S, Brownlie D, Kato Y, et al. Monocytes Differentiate to Immune Suppressive Precursors of Metastasis-Associated Macrophages in Mouse Models of Metastatic Breast Cancer. Front Immunol. 2017;8:2004 pubmed publisher |
| Kortlever R, Sodir N, Wilson C, Burkhart D, Pellegrinet L, Brown Swigart L, et al. Myc Cooperates with Ras by Programming Inflammation and Immune Suppression. Cell. 2017;171:1301-1315.e14 pubmed publisher |
| Singh M, Vianden C, Cantwell M, Dai Z, Xiao Z, Sharma M, et al. Intratumoral CD40 activation and checkpoint blockade induces T cell-mediated eradication of melanoma in the brain. Nat Commun. 2017;8:1447 pubmed publisher |
| Roussey J, Viglianti S, Teitz Tennenbaum S, Olszewski M, Osterholzer J. Anti-PD-1 Antibody Treatment Promotes Clearance of Persistent Cryptococcal Lung Infection in Mice. J Immunol. 2017;199:3535-3546 pubmed publisher |
| Speranza M, Passaro C, Ricklefs F, Kasai K, Klein S, Nakashima H, et al. Preclinical investigation of gene-mediated cytotoxic immunotherapy and checkpoint blockade in glioblastoma. Neuro Oncol. 2017;: pubmed publisher |
| Ono Y, Pérez Gutiérrez A, Nakao T, Dai H, Camirand G, Yoshida O, et al. Graft-infiltrating PD-L1hi cross-dressed dendritic cells regulate antidonor T cell responses in mouse liver transplant tolerance. Hepatology. 2018;67:1499-1515 pubmed publisher |
| Zhang Y, Kurupati R, Liu L, Zhou X, Zhang G, Hudaihed A, et al. Enhancing CD8+ T Cell Fatty Acid Catabolism within a Metabolically Challenging Tumor Microenvironment Increases the Efficacy of Melanoma Immunotherapy. Cancer Cell. 2017;32:377-391.e9 pubmed publisher |
| Ferris S, Zakharov P, Wan X, Calderon B, Artyomov M, Unanue E, et al. The islet-resident macrophage is in an inflammatory state and senses microbial products in blood. J Exp Med. 2017;214:2369-2385 pubmed publisher |
| Hirose T, Tanaka Y, Tanaka A, Sakai H, Sasaki Y, Shinohara N, et al. PD-L1/PD-L2-expressing B-1 cells inhibit alloreactive T cells in mice. PLoS ONE. 2017;12:e0178765 pubmed publisher |
| Kleinovink J, Marijt K, Schoonderwoerd M, van Hall T, Ossendorp F, Fransen M. PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy. Oncoimmunology. 2017;6:e1294299 pubmed publisher |
| Seth P, Csizmadia E, Hedblom A, Vuerich M, Xie H, Li M, et al. Deletion of Lactate Dehydrogenase-A in Myeloid Cells Triggers Antitumor Immunity. Cancer Res. 2017;77:3632-3643 pubmed publisher |
| Davis R, Moore E, Clavijo P, Friedman J, Cash H, Chen Z, et al. Anti-PD-L1 Efficacy Can Be Enhanced by Inhibition of Myeloid-Derived Suppressor Cells with a Selective Inhibitor of PI3K?/?. Cancer Res. 2017;77:2607-2619 pubmed publisher |
| Juneja V, McGuire K, Manguso R, LaFleur M, Collins N, Haining W, et al. PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity. J Exp Med. 2017;214:895-904 pubmed publisher |
| Dieterich L, Ikenberg K, Cetintas T, Kapaklikaya K, Hutmacher C, Detmar M. Tumor-Associated Lymphatic Vessels Upregulate PDL1 to Inhibit T-Cell Activation. Front Immunol. 2017;8:66 pubmed publisher |
| Paynich M, Jones Burrage S, Knight K. Exopolysaccharide from Bacillus subtilis Induces Anti-Inflammatory M2 Macrophages That Prevent T Cell-Mediated Disease. J Immunol. 2017;198:2689-2698 pubmed publisher |
| Noguchi T, Ward J, Gubin M, Arthur C, Lee S, Hundal J, et al. Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape. Cancer Immunol Res. 2017;5:106-117 pubmed publisher |
| Payne K, Keim R, Graham L, Idowu M, Wan W, Wang X, et al. Tumor-reactive immune cells protect against metastatic tumor and induce immunoediting of indolent but not quiescent tumor cells. J Leukoc Biol. 2016;100:625-35 pubmed publisher |
| Herold M, Posevitz V, Chudyka D, Hucke S, Groß C, Kurth F, et al. B7-H1 Selectively Controls TH17 Differentiation and Central Nervous System Autoimmunity via a Novel Non-PD-1-Mediated Pathway. J Immunol. 2015;195:3584-95 pubmed publisher |
| Huang B, Zhan Y, Zong W, Yu C, Li J, Qu Y, et al. The PD-1/B7-H1 pathway modulates the natural killer cells versus mouse glioma stem cells. PLoS ONE. 2015;10:e0134715 pubmed publisher |
| Lei G, Zhang C, Lee C. Myeloid-derived suppressor cells impair alveolar macrophages through PD-1 receptor ligation during Pneumocystis pneumonia. Infect Immun. 2015;83:572-82 pubmed publisher |
| Murakami R, Denda Nagai K, Hashimoto S, Nagai S, Hattori M, Irimura T. A unique dermal dendritic cell subset that skews the immune response toward Th2. PLoS ONE. 2013;8:e73270 pubmed publisher |
| Bassi E, Moraes Vieira P, Moreira Sá C, Almeida D, Vieira L, Cunha C, et al. Immune regulatory properties of allogeneic adipose-derived mesenchymal stem cells in the treatment of experimental autoimmune diabetes. Diabetes. 2012;61:2534-45 pubmed |
| Scarlett U, Rutkowski M, Rauwerdink A, Fields J, Escovar Fadul X, Baird J, et al. Ovarian cancer progression is controlled by phenotypic changes in dendritic cells. J Exp Med. 2012;209:495-506 pubmed publisher |
| Meng Q, Yang P, Li B, Zhou H, Huang X, Zhu L, et al. CD4+PD-1+ T cells acting as regulatory cells during the induction of anterior chamber-associated immune deviation. Invest Ophthalmol Vis Sci. 2006;47:4444-52 pubmed |
